Skip to content
Screener

Edgewise Therapeutics, Inc. EWTX Total Liabilities & Equity

Total Liabilities & Equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$87.63B-7.4%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$3.19B-13.4%
Cytokinetics logo
CytokineticsCYTK
$1.92B+57.0%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$2.87B+8.0%
Dyne Therapeutics, Inc. logo
Dyne Therapeutics, Inc.DYN
$1.08B+49.8%
Solid Biosciences Inc. logo
Solid Biosciences Inc.SLDB
$420.58M+36.4%

Other financials

Income statement

See full
Operating income-$54.1M-17.7%
Net income-$49.0M-20.1%
EPS (diluted)-$0.46-7.0%

Balance sheet

See full
Cash & equivalents$33.2M-33.5%
Total debt$3.8M-16.8%
Total equity$493.2M+14.8%
Total assets$518.5M+14.1%

Cash flow

See full
Operating cash flow-$42.5M-12.4%
CapEx$260.0K+491%
Free cash flow-$42.8M-12.9%

Valuation

See full
Market cap$4.78B+236%
Enterprise value$4.75B+244%

Returns & leverage

See full
Return on equity-38.1%+13.4pp
Debt / equity0.0×
Current ratio22.6×+1.6×

Where this comes from

Reported directly by Edgewise Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:09 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056713
AssetsAs of / March 31, 2026 / (unaudited)As of / December 31, 2025
Stockholders' equity:
Preferred stock, $.0001 par value per share; 200,000,000 shares authorized and no shares issued or outstanding as of March 31, 2026 and December 31, 2025
Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 107,481,522 shares and 106,249,579 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively1010
Additional paid-in capital1,088,8291,067,941
Accumulated other comprehensive income (loss)(252)677
Accumulated deficit(595,384)(546,371)
Total stockholders' equity493,203522,257
Total liabilities and stockholders' equity$518,522$552,603

Item 1. Financial Statements (Unaudited)

FAQ

What is Edgewise Therapeutics, Inc.'s total liabilities & equity?
Edgewise Therapeutics, Inc. (EWTX) reported total liabilities & equity of $518.52M in Q1 2026.
How has Edgewise Therapeutics, Inc.'s total liabilities & equity changed year-over-year?
Edgewise Therapeutics, Inc.'s total liabilities & equity increased by 14.1% year-over-year, from $454.39M to $518.52M.
What is the long-term trend for Edgewise Therapeutics, Inc.'s total liabilities & equity?
Over 5 years (2020 to 2025), Edgewise Therapeutics, Inc.'s total liabilities & equity has grown at a 33.3% compound annual growth rate (CAGR), from $131.14M to $552.6M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Edgewise Therapeutics, Inc.'s total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude